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Thiol-ene click chemistry towards easy microarraying of half-
antibodies 
Rafael Alonso,a Pilar Jiménez-Meneses,a Jaime García-Rupérez,b María-José Bañuls*a and Ángel 
Maquieira*a
A UV light-induced thiol-ene coupling reaction (TEC) between half-
antibodies (hIgG) and vinyl functionalized glass surfaces was run for 
biosensing in the microarray format. The accomplished 
performance improved that obtained with whole antibodies. 
 The thiol-ene coupling reaction (TEC) fulfils all the desirable 
requirements of a click reaction.1 It is highly effective, proceeds 
in high yields under mild reaction conditions and does not 
generate side products. TEC is normally initiated by UV light, 
which induces the formation of a thiol radical that reacts with a 
carbon-carbon double bond and leads to a thioether. This 
reaction is extremely tolerant to a variety of functional groups 
and is orthogonal.2 Moreover, it can be performed in aqueous 
media, which allows this methodology to be used for 
biomolecules.3 All these features make the TEC reaction a very 
interesting methodology for the covalent immobilisation of 
biomolecules in microarray format and for its use in biosensing. 
 Liu et al recently reported the use of thiol-ene click 
chemistry for an efficient and cysteine-selective thiol–ene click 
reaction-based bioconjugation strategy using colloidal 
nanoparticles.4 They demonstrated its applicability with 
thiolated organic compounds, aptamers and enzymes (HRP), 
but not for antibodies, which is surely due to the difficulty of 
making free thiol moieties available in them. 
 In line with our previous studies on the microarraying of 
thiolated oligonucleotides onto silicon-based surfaces by means 
of TEC,5 we envisioned the use of UV light-induced thiol-ene 
coupling to pattern antibodies microarrays rapidly and cleanly. 
 Immunoglobulin G antibodies (IgG) are the most prominent 
class of immunoglobulins employed in biosensing. They consist 
of four subunits, two heavy protein chains (H) and two light 
protein chains (L). The two halves are connected through the 
hinge region by a number of disulphide bonds, which depends 
on both the species6 and the antibody subclass.7 IgG 
immobilisation is key in the development of sensing devices to 
detect analytes, such as proteins or drugs. IgGs can be 
immobilised either randomly or in an oriented fashion.8 The 
latter is especially relevant for immunosensing applications 
since the antibody’s paratopes must be available for antigens to 
be captured. Several approaches are reported for the oriented 
immobilisation of IgGs, of which the most relevant are those 
that employ protein A or G.9 Due to unique capabilities of the 
antibody microarray and its applicability in a range of 
biomedical projects, a series of different antibody microarrays 
have been developed, of which some have become 
commercially available.10 However, regardless the rapid 
technological advances in the last years, there are still technical 
issues that need to be overcome to ensure high-specificity and 
reproducibility of antibody arrays, to ensure high impact data 
and meaningful conclusions. The surface chemistry and the 
mode of antibody immobilization are within the experimental 
factors that may help to solve these problems. 
 Besides whole antibody, antibody fragments like Fab’ and 
scFv fragments can also be successfully employed as probes for 
immunosensing.11 For the purpose of using the TEC approach to 
create antibody microarrays, we selected half-antibodies (hIgG) 
as capture probes. Then the disulphide bonds bridging the two 
halves of an IgG must be properly reduced, which results in two 
half-antibodies that bear as many free-thiol groups as the 
disulphide bonds that exist in the hinge region.12 hIgG have 
been reported to covalently link to maleimide-functionalised 
surfaces13 and to chemisorb onto gold14 and zinc15 surfaces. 
However, a direct, rapid and efficient attachment of hIgGs on 
glass or other Si-based surfaces has not yet been reported.  
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Fig. 1 Reduction of Immunoglobulin G antibodies (IgG) to half-antibodies (hIgG) and their 
use to generate planar microarrays on alkene-functionalised surfaces. 
More importantly, none of the reported approaches allows the 
site-directed immobilisation of probes. Thus we hypothesised 
the use of UV light-induced thiol-ene coupling for the reaction 
between the exposed sulfhydryl groups in hIgG and alkene-
functionalised glass surfaces. The new free thiol moieties 
generated by the reduction of antibodies would be available for 
reaction via TEC with alkenes attached to surfaces, which would 
allow them to be immobilised in an oriented fashion, and be 
ready to be employed in biosensing (Fig. 1). 
 Anti-bovine serum albumin polyclonal antibodies (IgG 
αBSA), anti-human C-reactive protein monoclonal antibodies 
(IgG αCRP) and anti-cardiac troponin I monoclonal antibodies 
(IgG αcTnI) were chosen as capture probes for microarraying. 
hIgG were obtained by treating the commercially available 
whole antibodies with tris(2-carboxyethyl)phosphine 
(TCEP).12,16 When employing other reductants, such as 
mercaptoethylamine (MEA), over-reduction occurred, and 
additional disulphide bonds between light and heavy chains 
were cleaved, which led to loss of recognition capability. For the 
case of TCEP several temperatures, times, and concentrations 
were assayed. The chosen conditions were those providing the 
best biorecognition capability of the immobilised hIgG. The hIgG 
generated by TCEP reduction were characterised by SDS-PAGE 
electrophoresis (ESI†, Fig. S1). Additionally, in order to 
determine the available number of free thiol groups after 
reduction, hIgG were subjected to Ellman´s assay17 (for 
experimental details, see ESI†). This experimental procedure 
 
Fig. 2 Fluorescence intensities r3ecorded for the microarrays obtained by spotting 
hIgG αBSA and IgG αBSA at the 200 µg/mL concentration for the chips irradiated 
at 254 nm for either 0 or 5 seconds, and the subsequent incubation with 5 µg/mL 
AlexaFluor 647-labelled BSA. 
showed that the polyclonal hIgG αBSA prepared by TCEP 
reduction bore 3.7 free sulphhydryl groups while monoclonal 
hIgG αcTnI had 2.6 thiol groups. These values agree with the 
average number of disulphide bridges in the hinge region for the 
rabbit polyclonal and mouse monoclonal IgG2a subtype, 
respectively.18 Besides, the maintenance of the recognition 
ability indicated that the link between H and L was not 
disrupted. 
 Due to the presence of free thiols after the cleavage of 
disulphide bonds, the new generated hIgG were used for UV 
light-induced thiol-ene coupling (TEC) on vinyl-functionalised 
glass surfaces. Glass slides were activated by UV light irradiation 
and were subsequently functionalised by immersion in a 
solution of triethoxyvinylsilane in toluene (2%; 2h), which led to 
an alkene-coated surface. The water contact angle (WCA) 
increased from 24o for the non-functionalised surface to 77o for 
the organosilane-coated chips (ESI†, Fig. S2).  
The bovine serum albumin (BSA)/rabbit polyclonal hIgG 
αBSA system was selected as the model system to optimise the 
methodology. Thus freshly protein A purified polyclonal IgG 
αBSA was reduced with TCEP to the corresponding hIgG. 
AlexaFluor 647-labelled hIgG αBSA was dispensed over the 
vinyl-functionalised glass chips at different concentrations (0–
20 µg/mL). Then chips were irradiated for 5 s at 254 nm and 
were subsequently washed. By measuring the fluorescence 
emission with a homemade surface fluorescence reader (SFR),19 
the immobilised probe density was determined as 2.36±0.18 
pmol/cm2 which corresponds to the maximum theoretical 
immobilisation density for a half-antibody by assuming that the 
dimensions of an antibody are ca. 15 × 5 × 5 nm3. 
 Several hIgG αBSA solutions at different concentrations 
(between 25 and 500 µg/mL) were microarrayed over the vinyl-
functionalised glass chips, and irradiated with UV-light to induce 
TEC. Whole IgG αBSA antibodies were also immobilised for 
comparison purposes. After washing, chips were subsequently 
incubated for 30 min in the dark with different solutions of 
freshly prepared AlexaFluor 647-labelled BSA (BSA*). The 
fluorescence of the cleaned and dried chips was measured with 
the SFR. hIgG performed significantly better than the 
corresponding whole antibodies in all cases. The fluorescence 
intensity of the signal obtained for hIgG was 7-fold stronger 
than the signal obtained for the immobilised IgG. When 
comparing to the performance of a standard microarray created 
by immobilising the IgG onto an epoxylated surface, the 
fluorescence obtained for our microarray was up to 4-fold 
higher than for the case of the reference microarray The control 
experiments done in the absence of UV-light showed that 
irradiation was needed for the TEC reaction to take place and to 
immobilize the hIgG (Fig. 2). Under these experimental 
conditions, the sensitivity assay showed that the system can 
detect up to 0.2 µg/mL of labelled BSA when the hIgG is 
immobilised at concentrations that equal or were higher than 
50 µg/mL (Fig. 3). The reached sensitivity fell within the limit of 
detection (LOD) that was intrinsic to the detection system 
employed and the obtained BSA labelling ratio. The density of 
labelled protein retained on the surface by the immobilised  
hIgG αBSA 200 µg/mL
IgG αBSA 200 µg/mL
hIgG αBSA 200 µg/mL
IgG αBSA 200 µg/mL
hIgG αBSA 200 µg/mL
IgG αBSA 200 µg/mL
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Fig. 3 Fluorescence intensities recorded for the microarray of hIgG αBSA at different 
concentrations, incubated with decreasing concentrations of AlexaFluor 647-labelled 
BSA. The bar graph represents the data for the arrays of hIgG αBSA immobilised at 150 
µg/mL. 
hIgG resulted 1.54 picomol/cm2, which provides a 65% of 
biorecognition yield from the attached probes. 
 Once the BSA/polyclonal hIgG αBSA model system was fully 
optimised, the methodology was applied to detect analytes of 
clinical interest, C-reactive protein (CRP) and Cardiac Troponin I 
(cTnI). CRP is an annular pentameric protein found in blood 
plasma, whose levels rise in response to inflammation. The 
sensitivity of the CRP assay using the corresponding monoclonal 
hIgG was determined by preparing microarrays and incubating 
them with different concentrations of AlexaFluor 647 labelled 
CRP (CRP*, in 10% diluted human serum, following the 
procedure described for the BSA system. In this case, system 
performance was assessed by employing a commercially 
available microarray scanner to avoid the LOD constraints 
associated with the SFR (when employing the microarray 
scanner for the BSA/hIgG BSA model system the sensitivity 
reached was 2.3 ng/mL). The minimum concentration detected 
under these experimental conditions was 2 ng/mL for a hIgG 
αCRP microarray generated by TEC when employing a 50 µg/mL 
concentration of half-antibody (Fig. 4). 
 
Fig. 4 Sensing curve for recognising the AlexaFluor 647 labelled C-reactive protein (CRP*) 
by the hIgG αCRP microarray generated by UV-light-induced thiol-ene coupling for a 50 




Fig. 5 Sensitivity assay for cTnI using a sandwich immunoassay with hIgG αcTnI (50 
µg/mL) immobilised by TEC as the capture agent. 
 The immunodetection of cTnI was also carried out. cTnI is a  
cardiac and skeletal muscle protein considered to be the most 
sensitive and, significantly, the most specific marker in 
myocardial infarction diagnosis.20 Due to the fact that cTnI is 
most unstable to buffer changes, and it could not, therefore, be 
labelled with the Alexa Fluor fluorophore, a sandwich-type 
immunoassay had to be performed. Thus the detection of cTnI 
was done by creating microarrays of the hIgG of monoclonal 
cTnI by the TEC methodology as described above, and by 
incubating with different cTnI concentrations in 10% diluted 
human serum, and by finally developing with a labelled 
detection antibody. This optimised methodology obtained a 
sensitivity of 10 ng/mL of cTnI (Fig. 5).  
Finally, in order to test the selectivity of the optimised systems, 
microarrays were created following the same 
biofunctionalisation protocol with a row of each hIgG αBSA, 
hIgG αCRP and hIgG αcTnI. Some chips were incubated only 
with labelled BSA, others with labelled CRP, others with cTnI, 
and others with a mixture of the three targets, in 10% diluted 
human serum. Fluorescence was recorded after the 
development step with the labelled detection antibody for cTnI. 
All the results demonstrated the specificity of capture (Fig. 6). 
 
Fig. 6 Multiplexing assay in the microarray format for protein/antibody systems: 
BSA/hIgG αBSA, CRP/hIgG αCRP and cTnI/hIgG αcTnI. Incubating with (A) BSA* (10 
ng/mL); (B) CRP* (10 ng/mL); (C) cTnI (10 ng/mL); (D) mixture of BSA* (10 ng/mL), CRP* 
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 To the best of our knowledge, we herein report the first 
example of a UV light-induced thiol-ene coupling reaction 
between the free thiol groups present in half-antibodies and 
vinyl-functionalised surfaces to construct microarrays. The 
performance of these half-antibody microarrays generated by 
TEC dramatically improved the response compared to whole 
antibody microarrays, which is likely due to the fixed orientation 
of hIgG under these conditions. The methodology described 
herein allowed us to successfully determine interesting analytes 
(CRP and cTnI in this case), perform multiplexing experiments, 
and represent a non-reported approach for the effective 
immobilisation of antibodies under very mild, rapid and 
biocompatible conditions. The approach is applicable to a wide 
range of materials that can be functionalised with organosilane 
chemistry, and can selectively pattern antibodies on the surface 
by using selective irradiation through a photomask. 
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